BeiGene gets the ball rolling on its 3rd IPO — and this one is ex­pect­ed to fetch $3B

BeiGene was among the first Chi­na-based biotech com­pa­nies to list on Nas­daq and made his­to­ry by rais­ing $903 mil­lion in its sec­ondary list­ing in Hong Kong. Now, it’s ready to pull a hat trick as it launch­es its pro­posed IPO on Shang­hai’s STAR Mar­ket.

The biotech is re­port­ed­ly look­ing to raise as much as $3 bil­lion from sell­ing about 8.62% of its to­tal out­stand­ing shares.

With roots in Bei­jing, BeiGene has plant­ed its foot all the way across the Pa­cif­ic un­der found­ing CEO John Oyler, who has of­fered a grand vi­sion to de­liv­er world-class on­col­o­gy drugs by lever­ag­ing dis­cov­ery tal­ents and clin­i­cal tri­al in­fra­struc­ture in Chi­na while look­ing to the world — a vi­sion that sees “no bor­ders.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER